References - Homocysteine in Protein Structure/Function and Human Disease - page 132

20. Mudd SH, Levy HL, Kraus JP. Disorders of transsulfuration. In: Scriver CR, Beaudet AL, Sly
WS, Valle D, Childs B, Kinzler KW, Vogelstein B, editors. The metabolic and molecular
bases of inherited disease, vol. 2. 8th ed. New York, NY: Mc Graw-Hill; 2001. p. 2007-56.
21. Richie Jr JP, Leutzinger Y, Parthasarathy S, Malloy V, Orentreich N, Zimmerman
JA. Methionine restriction increases blood glutathione and longevity in F344 rats. FASEB
J. 1994;8(15):1302-7.
22. Sanz A, Caro P, Ayala V, Portero-Otin M, Pamplona R, Barja G. Methionine restriction
decreases mitochondrial oxygen radical generation and leak as well as oxidative damage to
mitochondrial DNA and proteins. FASEB J. 2006;20(8):1064-73.
23. Komninou D, Leutzinger Y, Reddy BS, Richie Jr JP. Methionine restriction inhibits colon
carcinogenesis. Nutr Cancer. 2006;54(2):202-8.
24. Harker LA, Slichter SJ, Scott CR, Ross R. Homocystinemia. Vascular injury and arterial
thrombosis. N Engl J Med. 1974;291(11):537-43.
25. Thampi P, Stewart BW, Joseph L, Melnyk SB, Hennings LJ, Nagarajan S. Dietary homocys-
teine promotes atherosclerosis in apoE-deficient mice by inducing scavenger receptors
expression. Atherosclerosis. 2008;197(2):620-9.
26. Boers G. Moderate hyperhomocysteinaemia and vascular disease: evidence, relevance and
the effect of treatment. Eur J Pediatr. 1998;157 Suppl 2:S127-30.
27. Krupkova-Meixnerova L, Vesela K, Vitova A, Janosikova B, Andel M, Kozich V. Methio-
nine-loading test: evaluation of adverse effects and safety in an epidemiological study. Clin
Nutr. 2002;21(2):151-6.
28. Cottington EM, LaMantia C, Stabler SP, Allen RH, Tangerman A, Wagner C, et al. Adverse
event associated with methionine loading test: a case report. Arterioscler Thromb Vasc Biol.
2002;22(6):1046-50.
29. Kluijtmans LA, Boers GH, Kraus JP, van den Heuvel LP, Cruysberg JR, Trijbels FJ, et al. The
molecular basis of cystathionine beta-synthase deficiency in Dutch patients with
homocystinuria: effect of CBS genotype on biochemical and clinical phenotype and on
response to treatment. Am J Hum Genet. 1999;65(1):59-67.
30. Yap S, Boers GH, Wilcken B, Wilcken DE, Brenton DP, Lee PJ, et al. Vascular outcome in
patients with homocystinuria due to cystathionine beta-synthase deficiency treated chroni-
cally: a multicenter observational study. Arterioscler Thromb Vasc Biol. 2001;21

(12):2080-5.
31. Rosenblatt D, Fenton W. Disorders of transsulfuration. In: Scriver C, Beaudet A, Sly W,
Valle D, Childs B, Kinzler K, Vogelstein B, editors. The metabolic and molecular bases of
inherited disease. 8th ed. New York, NY: Mc Graw-Hill; 2001. p. 2007-56.
32. Visy JM, Le Coz P, Chadefaux B, Fressinaud C, Woimant F, Marquet J, et al.
Homocystinuria due to 5,10-methylenetetrahydrofolate reductase deficiency revealed by
stroke in adult siblings. Neurology. 1991;41(8):1313-5.
33. McCully KS. Vascular pathology of homocysteinemia: implications for the pathogenesis of
arteriosclerosis. Am J Pathol. 1969;56(1):111-28.
34. Refsum H, Nurk E, Smith AD, Ueland PM, Gjesdal CG, Bjelland I, et al. The Hordaland
Homocysteine Study: a community-based study of homocysteine, its determinants, and
associations with disease. J Nutr. 2006;136(6 Suppl):1731S-40.
35. Nygard O, Nordrehaug JE, Refsum H, Ueland PM, Farstad M, Vollset SE. Plasma homocys-
teine levels and mortality in patients with coronary artery disease. N Engl J Med. 1997;337
(4):230-6.
36. Wald DS, Law M, Morris JK. Homocysteine and cardiovascular disease: evidence on
causality from a meta-analysis. BMJ. 2002;325(7374):1202.
37. Anderson JL, Muhlestein JB, Horne BD, Carlquist JF, Bair TL, Madsen TE, et al. Plasma
homocysteine predicts mortality independently of traditional risk factors and C-reactive
protein in patients with angiographically defined coronary artery disease. Circulation.
2000;102(11):1227-32.